Karo falls after MK-6913 dropped for hot flashes

Karo Bio AB (SSE:KARO) fell SEK0.70 (10%) to SEK6.25 on Wednesday after partner Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-6913 to treat hot flashes. Karo said the estrogen receptor agonist missed undisclosed, pre-defined efficacy criteria for advancing to the second stage of a Phase II trial in postmenopausal women. Karo said Merck is evaluating its options for future studies involving MK-6913. ...